



SUMMARY OF SUBGROUP DECISIONS FOR GMMMG APPROVAL – 10th February 2022

SUBGROUP DECISIONS WITH SIGNIFICANT FINANCIAL OR COMMISSIONING IMPACT

CRG DECISIONS September 2021

Product and indication	Status Assigned	Include in formulary	Notes on Decision	Cost impact	Commissioning/ Service implications	GMMMG decision
None						N/A

MMSG Decisions November 2021

None						N/A
------	--	--	--	--	--	-----

SUBGROUP DECISIONS WITHOUT SIGNIFICANT FINANCIAL OR COMMISSIONING IMPACT

CRG DECISIONS September 2021

Product and indication	Status Assigned	Include in formulary	Notes on Decision	Cost impact	Commissioning/ Service implications	FINAL DECISION
Insulin degludec for T1 and T2DM	GREEN following specialist initiation and GREY (criterion 3)	Update chapter 6	<p>The proposed amendments incorporate the recommendations in NG17, the existing GMMMG insulin degludec recommendation and the RAG assignment agreed by the FMESG in 2019.</p> <p>Insulin degludec for T1 and T2DM to be added to formulary and RAG list as GREEN following specialist initiation and GREY (criterion 3) only for use:</p> <ul style="list-style-type: none"> • If there is particular concern about nocturnal hypoglycaemia despite optimisation of medication regimen • For patients with an unpredictable lifestyle (e.g. shift workers) 	Nil – reflects existing practice	None	Approved

			<ul style="list-style-type: none"> For patients who need help from a carer or healthcare professional to administer injections [NEW from NG17] 			
Dapsone 50mg & 100mg tablets as second line option for Pneumocystis carinii pneumonia (PCP) prophylaxis	Green following specialist initiation	No	Dapsone is currently on GMMMG formulary as GREEN following specialist initiation for leprosy and dermatitis herpetiform. Use for PCP prophylaxis is currently not covered. Dapsone will be used as a second line option for patients who have an allergy to co-trimoxazole (trimethoprim/ sulfamethoxazole) who are transplant recipients or receiving augmented immunosuppression for autoimmune conditions. This is limited to an estimated 5 patients per year from specialist centres	Annual drug costs for 5 patients = £1600 per year	None	Approved
Isoniazid 100mg tablets for TB prophylaxis in renal patients considered to be at high risk of developing TB	Green following specialist initiation	No	This drug is not currently on the formulary for this indication only as GREEN following specialist initiation for <i>treatment</i> of TB. Off-label use of isoniazid for TB prophylaxis in this population is supported by guidance from the Kidney Disease: Improving Global Outcomes (KDIGO) and the British Thoracic Society. Treatment estimated to be for 50 patients per year	Annual drug cost for 50 patients = £24,800 per year	None	Approved
Duloxetine 90mg & 120mg capsules	Green & Grey (criterion 2)	Add to chapter 4	CRG were asked to give these formulations a DNP status on the basis there are more cost-effective products available. CRG members thought there may be a situation where the pill burden for patients was an issue. Therefore the recommendation is as Green and Grey only for use where the prescriber believes that patient's pill burden is high enough to justify the extra cost associated with the use of these formulations.	Cost-saving	None	Approved

MGSG Decisions November 2021

<p>Primary Care rebate schemes</p>	<p>N/A</p>	<p>N/A</p>	<p>3 PCRS were reviewed by MGSG at their November meeting, these were:</p> <ul style="list-style-type: none"> • Pradaxa (dabigatran) – recommendation to reject approved • Dacepton D-mine (apomorphine) pen – manufacturer has since withdrawn rebate scheme • Dacepton D-mine (apomorphine) pump – recommendation to reject approved 	<p>Nil</p>	<p>None</p>	<p>Approved</p>
<p>Melatonin Shared Care Protocol for children and adolescents</p>	<p>N/A</p>	<p>N/A</p>	<p>MGSG considered an updated version of this GMMMG SCP in order to replace the expired version hosted on the GMMMG website.</p> <p>MGSG deemed there to be insufficient information on the long term use, withdrawal from and the management of drug holidays of melatonin. It has been referred back to CRG for further information to be included</p>	<p>Nil</p>	<p>None at this stage</p>	<p>Not Approved</p>